ロード中...
Data on migration of the non-invasive breast cancer cell line, MCF-7 treated with Bevacizumab using Real Time Cell Analyzer (RTCA)
Bevacizumab or Avastin® (Av), the recombinant antibody targeting VEGF, improves progression-free but not overall survival of metastatic breast cancer patients due to development of Av resistance. We showed that Av-therapy-induced inflammatory microenvironment contributes to the refractoriness to Av...
保存先:
| 出版年: | Data Brief |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2018
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6327074/ https://ncbi.nlm.nih.gov/pubmed/30671510 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dib.2018.12.059 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|